Guidance
MCV 5-dose Option Overview
This slide deck provides a concise overview of the 5-dose measles-containing vaccine (MCV) vial option for routine immunization programs. It is intended for EPI managers, immunization partners, and country decision-makers considering whether a switch from 10-dose to 5-dose measles or MR vials could improve coverage and reduce missed opportunities for vaccination.
The resource summarizes the rationale for the 5-dose option, expected program implications, product and cost considerations, cold chain requirements, and key questions for country decision-making. It also includes frequently asked questions to help teams assess whether the 5-dose presentation is a good fit for their context and how to plan for implementation.
Authors
Languages
- English
Publication year
2026
Type
Guidance
Categories
- Vaccines & delivery devices
Diseases
- Measles
- Rubella
Tags
- Vaccine presentation and packaging
MCV5 PHASE 1
You can find more information about "MCV5 PHASE 1" in the following Hot Topics:
| Title | Author | Year | Type | Language |
|---|---|---|---|---|
| Measles and Measles-Rubella (MR) Vaccine Five-Dose Vial Presentation - Fact Sheet 2022 - 2023 | UNICEF, World Health Organization (WHO) | 2022 | Guidance | English |
| MCV 5-dose Research and Resources | Linksbridge | 2022 | Report | English |
| MCV 5-dose National Impact Assessment Tool | Linksbridge | 2026 | Tool | English, French |
| Experiences with the MCV 5-dose Switch from Africa’s EPI | UNICEF | 2024 | Case study | English |
| How To Use: Step-by-Step Instructions for the MCV 5-dose National Impact Assessment Tool | Linksbridge | 2025 | User guide | English |
| MCV 5-dose Option Overview | Linksbridge | 2026 | Guidance | English |
| MCV 5-dose 2-Pager | Linksbridge | 2026 | Guidance | English |
